Research Article
The Contribution of Drugs and Helicobacter pylori to Gastric Mucosa Changes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Table 6
Gastric mucosal changes at EGD in the patient groups according to the administration of glucocorticoids and the rate of H. pylori detection.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes: The percentage of patients with appropriate GM changes in the glucocorticoid, non-glucocorticoid, and comparison groups was calculated from the total number of patients in the corresponding group. The percentage of H. pylori-positive patients was calculated from the number of those with appropriate GM changes in the glucocorticoid, non-glucocorticoid, and comparison groups. P1 - comparison of the number of patients with and without appropriate GM changes in the comparison and glucocorticoid groups. P2 - comparison of the number of H. pylori-positive and H. pylori-negative patients with an appropriate GM change in the comparison and glucocorticoid groups. P3 - comparison of the number of patients with and without appropriate GM changes in the glucocorticoid and non-glucocorticoid groups. P4 - comparison of the number of H. pylori-positive and H. pylori-negative patients with an appropriate GM change in the glucocorticoid and non-glucocorticoid groups. |